The Glycopeptide PV-PS A1 Immunogen Elicits Both CD4+ and CD8+ Responses

Area of Science:

• Immunology
• Vaccine Development
• Glycobiology

Background:

• Zwitterionic polysaccharide PS A1 is a promising vaccine carrier for CD4+ T-cell responses against tumor-associated carbohydrate antigens (TACAs).
• PS A1's inability to elicit MHCI-dependent CD8+ T-cell responses may limit its use in cancer, infectious, and viral vaccines.
• This study aimed to overcome PS A1's MHCI independence by incorporating an MHCI epitope.

Purpose of the Study:

• To develop a novel vaccine carrier by combining PS A1 with an MHCI epitope.
• To establish a vaccine that is dependent on both MHCI and MHCII pathways.
• To investigate the immune response elicited by the novel glycopeptide construct.

Main Methods:

• Synthesis of a glycopeptide construct (Tn-PV-PS A1) combining a Thomsen-nouveau TACA with a poliovirus (PV) peptide and PS A1.
• Immunization of C57BL/6 mice with the Tn-PV-PS A1 construct and a control peptide.
• Extraction and analysis of T-cells from mouse spleens using cell proliferation assays.

Main Results:

• The Tn-PV-PS A1 construct elicited a robust CD4+ and CD8+ T-cell immune response.
• Cytotoxic T lymphocytes generated were specific for the Tn-PV antigen.
• These cytotoxic T lymphocytes effectively lysed Tn-expressing EL4 cells.

Conclusions:

• The modified PS A1 (PV-PS A1) acts as a robust carrier, dependent on both MHCI and MHCII pathways.
• This represents the first report of MHCI dependence in a zwitterionic polysaccharide.
• The findings support the potential of this novel carrier for broader vaccine applications.